Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Joseph Baroldi, executive vice president and chief business officer at Ionis Pharmaceuticals Inc (NASDAQ:IONS), sold 1,625 shares of common stock on October 6, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $69.3693, for a total value of $112725. The prices for the transactions ranged from $69.36 to $69.41. The sale comes as the stock trades near its 52-week high of $71.87, having surged 174% over the past six months. According to InvestingPro analysis, the stock currently appears overvalued with technical indicators suggesting overbought conditions.
Following the transaction, Baroldi directly owns 30,301 shares of Ionis Pharmaceuticals. An additional 3,071 shares are indirectly owned by spouse.
The sale was executed under a Rule 10b5-1 trading plan adopted on May 2, 2025.
In other recent news, Ionis Pharmaceuticals has been the focus of several analyst updates and strategic announcements. The company recently held its Innovation Day, during which it shared longer-term revenue guidance and highlighted positive Phase 3 results for its drug Tryngolza/olezarsen. This event also included preliminary Phase 1 data for a next-generation ApoC-III siRNA candidate. Following these developments, Oppenheimer raised its price target for Ionis to $90, citing progress in the company’s pipeline, particularly after positive trials of olezarsen and zilganersen. JPMorgan also upgraded Ionis from Neutral to Overweight, increasing its price target to $80, following successful Phase III data in Alexander Disease and other promising updates. Stifel, while maintaining a Hold rating, significantly raised its price target from $43 to $67, reflecting an updated assessment of the TTR market. Additionally, Ionis has outlined an ambitious growth strategy, planning four product launches by 2026, with two already achieved in less than nine months. CEO Brett P. Monia also mentioned expectations for four partner-led launches by the end of 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.